| Authors | Xiaochun Liu, Patricia Lorusso, Monica Mita, Sarina Piha-Paul, David S Hong, Siqing Fu, Lacey McQuinn, Ekaterine Asatiani, Lawrence A Doyle, Helen X Chen, Kenneth R Hess, Razelle Kurzrock, Aung Naing |
| Journal | The oncologist
(Oncologist)
Vol. 19
Issue 4
Pg. 426-8
(Apr 2014)
ISSN: 1549-490X [Electronic] England |
| PMID | 24668327
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural)
|
| Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
- Protein Kinase Inhibitors
- cixutumumab
- Niacinamide
- temsirolimus
- Metformin
- MTOR protein, human
- TOR Serine-Threonine Kinases
- Sirolimus
|
| Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Female
- Humans
- Male
- Metformin
(therapeutic use)
- Middle Aged
- Mucositis
(chemically induced, epidemiology)
- Niacinamide
(analogs & derivatives, therapeutic use)
- Protein Kinase Inhibitors
(adverse effects, therapeutic use)
- Retrospective Studies
- Sirolimus
(adverse effects, analogs & derivatives, therapeutic use)
- TOR Serine-Threonine Kinases
(antagonists & inhibitors)
- Treatment Outcome
- Young Adult
|
